Mullen Group Ltd. Announces Declaration of Monthly Dividend
Get Alerts MTL Hot Sheet
Join SI Premium – FREE
OKOTOKS, ALBERTA -- (Marketwired) -- 01/20/17 -- The Board of Directors of Mullen Group Ltd. (TSX: MTL) ("Mullen Group" and/or the "Corporation") announced today that it has declared a monthly dividend of $0.03 per Common Share payable to the holders of record of Common Shares at the close of business on January 31, 2017. The dividend will be paid on February 15, 2017.
For Canadian resident shareholders, this dividend is designated as an "eligible dividend" for purposes of the enhanced dividend tax credit rules contained in the Income Tax Act (Canada) and any corresponding provincial and territorial tax legislation.
Mullen Group is a company that owns a network of independently operated businesses. The Corporation is recognized as one of the leading suppliers of trucking and logistics services in Canada and provides a wide range of specialized transportation and related services to the oil and natural gas industry in western Canada - two sectors of the economy in which Mullen Group has strong business relationships and industry leadership. The corporate office provides management and financial expertise, technology and systems support, shared services and strategic planning to its independent businesses.
Mullen Group is a publicly traded corporation listed on the Toronto Stock Exchange under the symbol "MTL". Additional information is available on our website at www.mullen-group.com or on SEDAR at www.sedar.com.
Contacts: Mullen Group Ltd. Mr. Murray K. Mullen Chairman of the Board, Chief Executive Officer and President Telephone: 403-995-5200 Mullen Group Ltd. Mr. P. Stephen Clark Chief Financial Officer Telephone: 403-995-5200 Mullen Group Ltd. Mr. Richard J. Maloney Senior Vice President Telephone: 403-995-5200 Fax: 403-995-5296
Source: Mullen Group Ltd.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mullen Group Ltd. Announces Declaration of Monthly Dividend
- Aulos Bioscience to Present Updated Phase 1/2 Clinical Trial Results for Novel IL-2 Therapeutic AU-007 in Advanced Solid Tumor Cancers at 2024 ASCO Annual Meeting
- D2L Releases 2024 Sustainability Report
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!